1085 results about "Infertility" patented technology

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV (“DPP-IV”), pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes, metabolic syndrome (syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

A method is provided for the improvement of implantation rates and / or pregnancy rates in a female mammal, comprising administering to a female mammal in whom pregnancy is desired an effective amount of (a) a nitric oxide synthase substrate, a nitric oxide donor, or both, optionally in combination with (b) a progestin, and, (c) optionally, in further combination with an estrogen. A method is also provided for fertility control for a female mammal, comprising administering to a female mammal in whom pregnancy is not desired and at risk for becoming pregnant an effective amount of nitric oxide synthase inhibitor in combination with an antiprogestin. Pharmaceutical compositions are also provided.

Methods, compositions and kits for determining the developmental potential of one or more embryos or pluripotent cells and / or the presence of chromosomal abnormalities in one or more embryos or pluripotent cells are provided. These methods, compositions and kits find use in identifying embryos and oocytes in vitro that are most useful in treating infertility in humans.

The present invention relates to a method of making novel dipeptidyl peptidase-IV ("DPP-IV') inhibitor compounds useful for treating, inter alia, diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of making 3,3,4,4-tetrafluoropyrrolidine, a starting material utilized in the afore-mentioned method for preparing DPP-IV compounds.

Provided are stabilized follicle stimulating protein (FSP) dry powder compositions for aerosolized delivery to the deep lung, methods of preparing and administering such compositions, and methods for treating infertility involving administering the dry powders by pulmonary delivery to the deep lung.

In an in vitro fertilization method, a woman is treated with a hypothalamic hormone and / or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof for a short period of time and, thereafter, using in vitro oocyte maturation egg or eggs are retrieved from the woman and are maturated using a meiosis activating compound.

The present invention is directed to methods of increasing oocyte production in a mammal. More specifically, the specification describes methods and compositions for inducing follicular maturation using a PDE inhibitor. The inhibitor may be used alone at high doses. Alternatively, the follicular maturation is achieved by combining a low dose of FSH with the PDE inhibitor treatment.

"The present invention provides non-peptidic amino derivatives, their therapeutic use as well as pharmaceutical compositions that possess activity as Follicle Stimulating Hormone (FSH) agonists and are useful in the treatment of infertility. In particular, the invention provides derivatives."

A method is provided for the improvement of implantation rates and / or pregnancy rates in a female mammal, comprising administering to a female mammal in whom pregnancy is desired an effective amount of (a) a nitric oxide synthase substrate, a nitric oxide donor, or both, optionally in combination with (b) a progestin, and, (c) optionally, in further combination with an estrogen. A method is also provided for fertility control for a female mammal, comprising administering to a female mammal in whom pregnancy is not desired and at risk for becoming pregnant an effective amount of nitric oxide synthase inhibitor in combination with an antiprogestin. Pharmaceutical compositions are also provided.

The present invention relates to a method of making novel dipeptidyl peptidase-IV ("DPP-IV') inhibitor compounds useful for treating, inter alia, diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of making 3,3,4,4-tetrafluoropyrrolidine, a starting material utilized in the afore-mentioned method for preparing DPP-IV compounds.

A method of genotyping women experiencing infertility for non-physical reasons in order to identify the presence of the rs4238001 and / or rs10846744 mutation of the SCARB1 gene and, upon identifying the presence of one or both genetic mutations, administering a tailored therapeutic regimen to restore fertility by either one or a combination of 1) mediating the flux of cholesterol resulting from the mutation by therapeutic use of the cholesterol medication probucol and / or other cholesterol altering medications, and / or 2) amplifying the presence of hormone progesterone by therapeutic use of progestational and progestin medications.

In vitro fertilization can be improved by adding a meiosis activating compound.

Methods and computer-based systems for facilitating assessment of clinical infertility are provided. The methods and systems can be implemented to, for example, facilitate assessment of a subject for an in vitro fertilization treatment cycle, including determining probability of a live birth event. The methods and systems can be implemented to, for example, facilitate a determination of success implantation of embryos, selection of an optimal number of embryos to transfer, and determination of success in subsequent in vitro fertilization treatment cycles following an unsuccessful treatment cycle.

The invention provides novel heterodimeric fusion proteins comprising a first polypeptide including an alpha subunit of FSH (αFSH) linked directly or indirectly to a binding partner of neonatal Fc receptor (FcRn) and a second polypeptide including a beta subunit of FSH (βFSH) linked directly or indirectly to an FcRn binding partner. In one embodiment the FcRn binding partner includes an Fc fragment of an immunoglobulin, e.g., an Fc fragment of IgG. Also provided are methods making and using the fusion proteins of the invention. The invention provides a method for increasing fertility in a subject and a method for treating a subject having a disease state responsive to treatment by FSH.

The invention relates to a Chinese medicinal preparation for treating facial chloasma, which is the medicinal preparation prepared from 77 raw material medicaments such as peach seed, safflower, danshen root, red paeony root and hawthorn fruit. The medicinal preparation is powder, tablets, pills, capsules, electuary or oral liquid. A preparation method of the Chinese medicinal preparation comprises the following steps of: (1) sieving and crushing the raw material medicaments; (2) sieving, and taking screening; (3) disinfecting and sterilizing to obtain medicinal raw powder; and (4) preparing the medicinal raw powder into tablets, granules, pills or capsules. The preparation method also can comprise the following steps of: (1) preparing the raw material medicaments into medicinal water extracting solution; (2) preparing the medicinal water extracting solution into the oral liquid; (3) drying, crushing and sieving the medicinal water extracting solution, taking screening, disinfecting and sterilizing to obtain medicinal extracting powder; and (4) preparing the medicinal extracting powder into tablets, granules, electuary or capsules. The Chinese medicinal preparation has a formula based on Chinese medicinal theory, and makes five internal organs healthy, and Yin and Yang balanced. The Chinese medicinal preparation mainly treats facial chloasma, freckles and facial pigmentation, treats hair loss caused by vitality stagnation and blood stasis, and has good curative effect on irregular cycles and infertility. The Chinese medicinal preparation is prepared from pure Chinese medicaments and has the advantages of diversiform formulations, convenient use, safety, reliability, no toxic or side effects, and suitability for long term usage.

A seat (chair, stool, etc.) has a seat base with a contoured front that is recessed in the middle. The recess extends towards a seating center and / or in a downward direction, creating an open area for seated person. The open area is located under the body part around the testes of a seated male person so that the dispersion of body heat from that area via air circulation will not be blocked by the seat base, and at the same time, the pressure between the testes area and the seat base will be reduced or eliminated, thereby improving the physiological condition for sperm, and in turn, may increase sperm activity and may reduce the possibility of infertility.

The invention discloses a rapid ecological restoration method for rock-soil side slopes, and relates to the field of ecological management for the rock-soil side slopes. The rapid ecological restoration method includes: (1) cleaning a rock-soil side slope; (2) paving a high-tensile net; (3) preparing basic materials for vegetation growth; (4) allocating vegetation, mixedly planting seeds and grass blades of shrubs and herbage plants endurable to draught and infertility and selecting rock-soil side slope protective Bermuda grass blades; (5) subjecting the vegetation to spray-planting; and (6) maintaining and managing. Since the rock-soil side slope protective Bermuda grass blades are selected to protect the rock-soil side slopes, the rapid ecological restoration method is efficient and rapid; the basic materials for the vegetation growth are easy to obtain, simple to prepare, scientific to prepare, capable of effectively meeting requirements on nutrient and moisture of the vegetation, beneficial to flourishing and long-term growth of the vegetation and the like; and the herbage plants and the shrubs endurable to draught and infertility are selected as the vegetation to be planted mixedly, so that the rapid ecological restoration method is good in landscape allocation effect. The rapid ecological restoration method is applicable to ecological restoration in earth-rock mountain regions, and is particularly beneficial to stability of eco-fragile regions with bare rocks.

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

A method and device to conform with the glans penis to recover ejaculated semen completely, to prevent the loss of initial sperm rich epididymal fractions, to avoid the use of a condom for masturbation, to eliminate the multi-step transfers of semen following ejaculation that are common with current methods, and to provide a single device that contains a semen collecting chamber that fits onto a glans penis. The device provides a storage and measuring reservoir, an optional cap, and a vertical stand in one integrally formed module in a sterile pack. The device and method will have multiple uses in a variety of contexts including, but not limited thereto: in the diagnosis of infertility, in semen donation, in vitro fertilization (IVF) / intra-cytoplasmic sperm injection (ICSI) clinics, hospitals, forensic laboratories and research laboratories and will be included in kits intended for over-the-counter sperm testing devices

The invention discloses a long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc) and a preparation method thereof. The recombinant hFSH-Fc is a dimerization fusion protein. An amino acid sequence of the hFSH-Fc comprises an hFSHbeta subunit, CTP (carboxy-terminal peptide), an hFSHalpha subunit, a flexible peptide linker and a human IgG (immunoglobulin G)2 Fc variant from the N terminal to the C terminal in sequence. The hFSH-Fc has longer half-life in vivo and smaller side effects than existing hFSH. The invention also relates to an application of a recombinant hFSH-Fc composition to preparation of drugs for treating and / or preventing infertility.

The present compounds are intermediates for the preparation of quinoline derivatives and compositions having gonadotropin-releasing hormone antagonistic activity useful as propylactics or therapeutic agent for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer (e.g. prostatic cancer, uterine or cervical cancer, breast cancer, pituitary adenoma), benign prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, polycystic ovary syndrome and acne vulgaris; are effective as a fertility controlling agent in both sexes (e.g. a pregnancy controlling agent and a menstrual cycle controlling agent); can be used as a male or female contraceptive, as an ovulation-inducing agent; can be used as an infertility treating agent by using a rebound effect owing to a stoppage of administration thereof; and are useful for modulating estrous cycles in animals in the field of animal husbandry, as agents for improving the quality of edible meat or promoting the growth of animals, and as agents for promoting spawning in fish.

The present invention relates to a method and device for male contraception. In one aspect, the method and device provide temporal and reversible infertility of mammal males without suppressing spermatogenesis. In an aspect, a method of contraception for use with reproductive cells that pass through a tube in a body is described in which energy is applied through the tube wall to some of the reproductive cells that pass through the tube to reduce fertilization ability of the some of the reproductive cells. In another aspect, the device is adapted for use with reproductive cells that pass through a tube in a body, and includes an energy transmitter that delivers energy to the reproductive cells that pass through the tube in the body.

The method of treatment for a genital tissue or reproductive organ of an infertility or impotence diagnosed patient is disclosed. The treatment has the steps of activating an acoustic shock wave generator or source to emit acoustic shock waves; and subjecting the genital tissue, reproductive organ or the entire reproductive region of the body to the acoustic shock waves stimulating said tissue, organ or body wherein the tissue, organ or body is positioned within a path of the emitted shock waves. The emitted shock waves can be convergent, divergent, planar or near planar.

The invention discloses a long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc) and a preparation method thereof. The hFSH-Fc is a dimerization fusion protein. An amino acid sequence of the hFSH-Fc comprises an hFSHbeta subunit, CTP (carboxy-terminal peptide), an hFSHalpha subunit, a flexible peptide linker and a human IgG (immunoglobulin G) Fc variant from the N terminal to the C terminal in sequence. The hFSH-Fc has longer half-life in vivo and smaller side effects than existing hFSH. The invention also relates to an application of a recombinant hFSH-Fc composition to preparation of drugs for treating and / or preventing infertility.

The invention is applicable within the food and pharmaceutical industry. More specifically, it relates to a novel strain of the species Bifidobacterium animalis subsp. lactis CECT 8145, the cell components, metabolites and secreted molecules thereof, which, incorporated into food and / or pharmaceutical formulations, can be used in the treatment and / or prevention of excess weight and obesity and related diseases such as metabolic syndrome, hypertension, glycemia, inflammation, type 2 diabetes, cardiovascular diseases, hypercholesterolemia, hormonal alterations, infertility, etc.

Disclosed is a method and composition for nutritional compositions containing -glucosidase inhibitors, and more specifically Touchi Extract and its uses in the treatment of many disorders. These disorders include diabetes, hyperlipidemia, obesity, Metabolic syndrome / Syndrome X, COPD, malabsorption, Crohn's disease, diarrhea, constipation, irritable bowel syndrome, human immunodeficiency virus, cystic fibrosis, non-alcoholic steatohepatitis, polycystic ovarian syndrome including associate infertility, and erectile dysfunction. Further, -glucosidase inhibitors, and more specifically Touchi Extract can be used to aid healing in critical care patients and for general wound healing. Additionally, -glucosidase inhibitors, including Touchi Extract can be used to enhance athletic performance.